The company’s IGC-AD1 is being evaluated in a Phase II trial to treat agitation in patients with Alzheimer’s associated dementia. Credit: Giovanni Cancemi via Shutterstock.com.

IGC Pharma has obtained a revolving line of credit worth $12m from the O-Bank’s Hong Kong branch in China to bolster research into Alzheimer’s disease. 

The company plans to utilise the funds as its working research capital for research. Three IGC molecules are currently being analysed for Alzheimer’s. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

IGC-AD1 is one of the company’s drug candidates and is being evaluated in a Phase II clinical trial for the potential treatment of agitation in patients with Alzheimer-associated dementia. 

Of the 146 targeted subjects, 16 have completed the study.

The firm has entered contracts with eight study centres to date, with discussions at seven further sites progressing. 

See Also:

In order to conclude the Phase II trial in the first quarter of 2024, IGC anticipates enrolling 15 to 20 subjects at 13-15 study sites every month.

IGC Pharma CEO Ram Mukunda stated: “We are thankful to O-Bank for their support and grateful for the continued support from Bradbury. 

“Together with our dedicated investors and partners, we are working towards our goal of developing innovative therapies for Alzheimer’s disease. With their support, we are focused on advancing IGC-AD1 and bringing hope and relief to millions of patients and families worldwide.”